Ionizable Lipid Compositions for Lung-Targeted CFTR Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene editing technologies for cystic fibrosis (CF) face challenges in delivering targeted editing to lung cells, particularly due to immunogenicity and integration issues with viral vectors, and non-viral lipid nanoparticle delivery has been limited to liver targets.
Innovation Solution
A nucleic acid editing system assembled with a lipid composition, comprising a guide nucleic acid, a heterologous polypeptide with an endonuclease, and a donor template nucleic acid, is used to enhance CFTR protein expression or activity by cleaving and repairing the CFTR gene or transcript in lung cells, achieving specific and efficient genetic correction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If viral vectors are used for in vivo gene editing, then targeted editing in lung cells can be achieved, but immunogenicity and integration events occur
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary delivery vehicle to transport CRISPR/Cas9 gene editing components to lung cells. This lipid-based delivery system replaces viral vectors, achieving targeted gene editing while avoiding immunogenicity and integration events associated with viral delivery methods.
Solution Approach 2:
The patent employs non-viral lipid nanoparticle delivery systems that are transient and do not integrate into the genome. These disposable delivery vehicles provide the necessary gene editing components temporarily and are then cleared by the body, avoiding long-term safety concerns of viral vectors.
2Manufacturing precision
If viral vectors are used for gene delivery, then targeted delivery to specific cells is possible, but concerns about dangerous integration events arise
Solution Approach 1:
Lipid nanoparticles serve as a non-integrating intermediary delivery system that can target specific lung cells without the risk of genomic integration. The lipid-based carrier delivers CRISPR components temporarily and is subsequently cleared, ensuring safety while maintaining targeted delivery capability.
3Reliability
If non-viral lipid nanoparticle delivery is used, then immunogenicity and integration concerns are avoided, but delivery is limited to liver targets
Solution Approach 1:
The patent modifies the lipid nanoparticle composition to achieve lung-specific targeting. By adjusting the lipid composition properties (such as ionizable lipids with specific pKa values), the delivery system is optimized for pulmonary delivery routes and lung tissue accumulation, enabling safe non-viral delivery to non-liver organs.
Solution Approach 2:
The patent changes physical and chemical parameters of the lipid nanoparticles (composition, size, surface charge, pKa) to enable targeting of lung cells instead of liver. These parameter modifications allow the same non-viral delivery platform to be adapted for different organ targets while maintaining safety advantages.
4Manufacturing precision
If gene editing is performed in lung cells, then CFTR mutations can be corrected, but delivery to lung cells remains challenging
Solution Approach 1:
The patent uses inhaled lipid nanoparticle formulations as an intermediary delivery method that leverages the natural pulmonary deposition of inhaled particles. This approach enables efficient delivery of CRISPR components to lung cells through the respiratory route, avoiding the need for invasive delivery methods while achieving effective gene editing in the target tissue.
Data Source
AI summary
Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.